Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05733611 2026-02-02

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2 Terminated

5 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06682806 2026-02-02

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 2 Terminated

6 enrolled

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis

NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Phase 2 Terminated

1 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

1 enrolled

GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

1 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Gastrointestinal

Colorectal Cancer Metastatic

NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Phase 2 Terminated

6 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT04805788 2025-12-31

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

Phase 2 Terminated

9 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05998447 2025-12-16

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Phase 2 Terminated

10 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Phase 2 Terminated

4 enrolled 10 charts

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05114213 2025-12-05

MASPAC

Phase 2 Terminated

9 enrolled

Gastrointestinal

Agnosia, Pancreatic Neoplasms

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

51 enrolled

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT04844970 2025-11-17

Anamorelin Study for Advanced Pancreatic Cancer

Phase 2 Terminated

4 enrolled 12 charts

Gastrointestinal

Anorexia, Cachexia, Pancreatic Neoplasms, Weight Loss

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Phase 2 Terminated

166 enrolled 43 charts

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT04504916 2025-11-10

MK-2140-002

Phase 2 Terminated

102 enrolled 36 charts

BreastGastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Phase 2 Terminated

13 enrolled

Gastrointestinal

Liver Neoplasms

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

Phase 2 Terminated

13 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Phase 2 Terminated

115 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT05199285 2025-10-03

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Phase 2 Terminated

15 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 2 Terminated

23 enrolled 15 charts

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02982694 2025-10-01

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Phase 2 Terminated

46 enrolled

Gastrointestinal

Colorectal Neoplasms, Activated Protein C Resistance

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT05350501 2025-09-29

CLAUDE

Phase 2 Terminated

1 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

BOLSTER

Alkagin Paste in the Prevention of Radiation Dermatitis

CAIRO7

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

TEJAS-2

PaTcH

TOGAR

LIDA-BII

E-DIS2

NeuroPrevPTSD

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

PARPi-PANC

Tamarack

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

NELMAS

HAITI

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

MASPAC

NIRADO

Anamorelin Study for Advanced Pancreatic Cancer

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

MK-2140-002

PAVO

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Nivolumab Combined With BMS-986253 in HCC Patients

DisTinGuish

Futibatinib in Patients With Specific FGFR Aberrations

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

CARMEN-BT01

CLAUDE